Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Nicole DeFeudis

Editor

Just five months after closing its $2.9 billion deal for MorphoSys, Novartis has recorded an $800 million impairment on the acquisition after a review of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Will CRISPR matter?

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Exclusive: CRISPR delivery startup, based on UC Berkeley and UCSF science, shuts down

Nvidia and the Arc Institute just dropped a really, really big AI bio model

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis takes $800M MorphoSys writedown mere months after closing acquisition